Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study.

Tuhina NeogiDavid J HunterMelvin ChurchillIvan ShirinskyAlexander WhiteAli GuermaziMasanari OmataRobert J FountaineGlenn PixtonLars ViktrupMark T BrownChristine R WestKenneth M Verburg

Published in: Arthritis research & therapy (2022)

ClinicalTrials.gov NCT02528188 . Registered on 19 July 2015.

Keyphrases

placebo controlled
double blind
open label
phase iii
rheumatoid arthritis
phase ii
knee osteoarthritis
clinical trial
study protocol
randomized controlled trial